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INTRODUCTION: The etiology of preeclampsia is not fully established. A few studies have shown a relationship
between natural coagulation inhibitors and preeclampsia.
OBJECTIVES: The purpose of this study was to investigate the status of natural coagulation inhibitors and active
protein C resistance (APC-R) in preeclampsia.
PATIENTS AND METHODS: We studied 70 women with preeclampsia recruited consecutively and 70 healthy
pregnant and 70 nonpregnant women as controls. Plasma protein C (PC), free protein S (fPS), antithrombin III (ATIII)
and APC-R were evaluated.
RESULTS: ATIII values were found to be significantly lower in preeclamptic patients than in the control groups (p,
0.001). Nevertheless, there was no significant difference between the healthy pregnant and nonpregnant women
groups (p=0.141). The fPS values of the preeclamptic and healthy pregnant groups were lower than that of the
nonpregnant group (p, 0.001), and the fPS value of the preeclamptic pregnant women was lower than that of
healthy pregnant women (p,0.001). The PC value of the preeclamptic pregnant women was lower than that of the
control groups (p, 0.001). The PC value of the healthy pregnant women was lower than that of the nonpregnant
women (p, 0.001). The mean APC activity values were lower in the preeclamptic patients than that of the control
groups (p, 0.001, p, 0.001). The APC-R positivity rates of the preeclamptic groups were higher than that of the
control groups (p,0.001).
CONCLUSIONS: This study demonstrated that ATIII, fPS, PC values and APC resistance were lower and APC-R
positivity was higher in preeclamptic women than in normal pregnant and nonpregnant women.
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INTRODUCTION
Preeclampsia is a clinical manifestation characterized by
hypertension, proteinuria and edema that occurs after the
20th week of pregnancy. It is identified as a cause of
maternal and fetal morbidity and mortality. Although the
etiology of preeclampsia remains unknown, it is suggested
that preeclampsia is associated with intervillous and spiral
artery thrombosis, vascular endothelium damage and
abnormalities of coagulation, leading to inadequate mater-
nal, fetal and placental circulation.
1 Immunologic adapta-
tion disorders, abnormal increase of vasoconstrictor tone,
nutritional factors, and genetic factors are some other
theories.
2–4 Preeclampsia and its association with thrombo-
philia remain controversial. Several investigators have
reported an association between thrombophilia and adverse
pregnancy outcomes caused by uteroplacental thrombosis,
i.e., severe intrauterine growth restriction and placental
abruption. Other groups, however, have failed to confirm
this association.
5–7
Protein S (PS) deficiency and active protein C resistance
(APC-R) have been found in severe preeclamptic women.
8
Antithrombin III (ATIII) deficiency is associated with
recurrent miscarriages.
9 Nevertheless, the extent of coagula-
tion problems induced by hypertensive disorders of
pregnancy is not clear yet. The primary objective of our
study was to determine the status of natural coagulation
inhibitors and APC-R in preeclampsia.
PATIENTS AND METHODS
Preeclamptic and healthy pregnant women who pre-
sented to the Obstetrics and Gynecology department of the
Medical Faculty Hospital of Yuzuncu Yil University and
Van Maternity Hospital were included in this study.
Seventy preeclamptic pregnant women (25 mild and 45
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1119severe) in the third trimester and a control group consisting
of 70 healthy pregnant and 70 healthy nonpregnant women
were included in the study. The healthy non–pregnant
group was recruited from the healthy relatives of patients
coming for check-ups at the Clinic of Internal Medicine,
Faculty of Medicine, Yuzuncu Yil University. The healthy
pregnant group was recruited from the pregnant women
coming to the Obstetrics Clinic at the Yuzuncu Yil
University, Faculty of Medicine.
The study design was approved by the Ethics Committee
of Yuzuncu Yil University, and written informed consent
was obtained from all participants.
Exclusion criteria for the preeclamptic group included a
history of any of the following: hypertension, smoking, deep
venous thrombosis in the patient and/or her family history,
and use of any kind of vitamin K antagonist or antic-
oagulant drugs.
Preeclamptic cases were classified as mild and severe
according to the criteria of the American College of
Obstetricians and Gynecologists.
10 Mild preeclampsia was
diagnosed in the presence of two criteria after the 20
th week
of pregnancy: a blood pressure of 140/90 mm/hg or higher
(after two consecutive measurements with an interval of six
hours) and proteinuria (300 mg of protein or higher in a 24-
hour urine specimen). In a pregnant woman who was
formerly normotensive, the presence of edema was not
considered to be a diagnostic criterion. Severe preeclampsia
was diagnosed when there were two or more of the
following severe preeclampsia diagnostic criteria: (a) sys-
tolic blood pressure exceeding 160 mm/Hg, diastolic blood
pressure exceeding 110 mm/Hg (blood pressure findings
must be observed twice at intervals of at least six hours); (b)
proteinuria measured with greater than 5 gr/24 hours or
three or four positive proteinuria findings detected with
dipstick; (c) oliguria (urine output of # 400 ml/24 hours);
(d) frontal headache or visual disturbances; (e) abnormal
liver function tests (alanine aminotransferase and aspartate
aminotransferase); (f) thrombocytopenia; and (g) pulmonary
edema or cyanosis.
Care was taken to match the age and week of pregnancy
of the healthy pregnant group and the preeclamptic group.
Pregnant women who had chronic renal disease, vascular
disease, had received anticoagulant treatment during
pregnancy or had a previous thromboembolic complication
were excluded from the study. Inclusion criteria for
nonpregnant healthy group were similar with preeclamptic
group for age; not using oral contraceptive and antic-
oagulant drug, being non-smoker or absence of thromboem-
bolic disease in the subject and her family history.
Blood was drawn from the antecubital veins of each of the
three groups of the study and placed into test tubes
containing 1 ml of 3.8% sodium-citrate. After centrifugation
of these specimens for ten minutes at room temperature and
25006g, the plasma specimens were placed into 1.5 ml tubes
and kept at -80 ˚C in the deep-freezer until analysis.
APC-R, PC, fPS and ATIII levels were studied in the
hematology laboratory of Yuzuncu Yil University Medical
Faculty Research and Practice Hospital using the fully
automatic coagulometer equipment (Diagnostica stago STA
Compact; France). The PC and ATIII values were deter-
mined by the colorimetric method using a kit (STA-
stachrom; France), and the results are given as percentages
for both PC and ATIII. To measure the fPS levels, the
immuno-turbidimetric method was applied using a kit
(STA-Liatest, France), and the results are given as percen-
tages. APC-R was determined by the coagulation method
(STA-Staclot APC-R method) using a specific kit
(Diagnostica Stago, France), and the results were given in
seconds. The tests were performed according to the
manufacturer’s guidelines. The laboratory reference spec-
trum was designated as 70–130% for PC, 60–140% for fPS
and 80–120% for ATIII. The normal range in healthy subjects
analyzed at our laboratory was 120–300 seconds for active
protein C (APC) activity, and results under 120 seconds
were accepted as APC-R.
Statistical Analysis
The sizes of the groups were equal to produce more
reliable and effective results. One-way ANOVA variance
analysis was used to compare the characteristics of the
groups, and the Duncan multiple comparison test was used
to identify the different groups. The designated level of
statistical significance was p,0.05.
RESULTS
The mean ages of the nonpregnant group, the healthy
pregnant group and the preeclamptic pregnant group were
25.94¡2.78, 25.37¡4.40 and 26.12¡3.32 years, respectively.
There were no statistical differences among the groups
(p=0.426). The mean gestational weeks of the preeclamptic
pregnant and healthy pregnant groups were 32.91¡1.63
and 33.20¡1.76 weeks, respectively. There was no statistical
difference between the groups (p=0.322).
The mean values of ATIII for the preeclamptic, healthy
pregnant and nonpregnant groups are given in Table 1.
There was no significant difference between the healthy
pregnant and nonpregnant women (p=0.141). When the
preeclamptic patients were compared to the healthy
pregnant and nonpregnant groups, however, the ATIII
value was found to be lower (p,0.001 and p,0.001,
respectively).
The mean values of fPS for the preeclamptic, healthy
pregnant and nonpregnant groups are given in Table 1. The
fPS values for the healthy pregnant and preeclampsia
groups were lower than that of the nonpregnant group
(p,0.001). The fPS value of the preeclamptic pregnant
Table 1 - ATIII, fPS, PC, APC mean activity and APC-R positivity of all groups.
Groups (n = 70) AT III (%) fPS (%) PC (%) APC (Activity sec) APC-R (+) (%)
Preeclampsia 77.38¡18.78 38.98¡11.28 74.40¡19.98 138.77¡31.26 17.14
Healthy pregnant 89.12¡24.13 49.54¡13.81 90.12¡10.74 176.41¡46.61 8.57
Non-pregnant 93.85¡12.15 74.94¡16.40 96.45¡15.62 186.19¡31.63 4.28
Values are presented as mean ¡ SD. ATIII: Antithrombin III; fPS: Free protein S; PC: Protein C; APC: Active protein C; APC-R: Active protein C resistance; sec:
second. p,0.05 was considered significant.
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(p,0.001).
The mean PC values of preeclamptic, healthy pregnant
and nonpregnant groups are given in Table 1. The PC value
of preeclamptic pregnant women was lower than those of
the other two groups (p,0.001). The PC level of the healthy
pregnant women was lower than that of the nonpregnant
women (p,0.001).
The mean APC values of the preeclamptic, healthy
pregnant and nonpregnant groups are given in Table 1.
There was no significant difference between the healthy
pregnant and nonpregnant groups (p=0.120). The APC
activity of the preeclamptic patients was significantly lower
than those of the healthy pregnant and nonpregnant
patients (p,0.001). Positivity rates of APC-R of the
preeclamptic and healthy pregnant groups are given in
Table 1. The APC-R positivity of preeclamptic patients was
significantly higher than those of the healthy pregnant and
the nonpregnant groups (p,0.001). There was no significant
difference between the healthy pregnant and the nonpreg-
nant groups (p=0.150).
The mean ATIII values of mild and severe preeclamptic
pregnant women are given in Table 2. The decrease in ATIII
in severe preeclamptic patients was significant compared to
that of mild preeclamptic patients (p,0.001). Other para-
meters (age, gestational age, ATIII, fPS, PC and APC values)
were not significantly different between these two groups
(Table 2).
DISCUSSION
During pregnancy, there is an increased tendency toward
coagulation and a decrease in fibrinolysis in the homeostatic
system.
11 PS levels decrease during healthy pregnancy, but
coagulation inhibitors, such as ATIII and PC, remain at
normal levels.
12–14 We found that the PC activity of the
healthy pregnant group was significantly lower than that of
the nonpregnant control group. The data provided by
Uchikova et al. for healthy pregnant and non-pregnant
women were consistent with our results.15 PC results in
preeclamptic pregnant women are contradictory. Aznar et
al. found that the PC levels of severe preeclamptic women
were significantly decreased compared to those of healthy
pregnant women.16 Gilabert et al. reported similar find-
ings.17 They emphasized that the decrease in PC levels
might be related to increased consumption. We found that
the PC activity of preeclamptic pregnant women was lower
than that of healthy pregnant and non-pregnant women. In
contrast, there were no significant differences between
the PC activities of the preeclamptic and healthy preg-
nant groups in two studies.
18,19
It is suggested that total and free PS levels decrease
gradually in healthy pregnant women during pregnancy,
and this condition may be caused both by increased protein
C resistance and increased levels of coagulation factors.
20,21
Consistent with the literature, we found that in healthy
pregnant women, the PS level was lower than in non-
pregnant controls. In two studies conducted on the PS state
in preeclampsia, the total and fPS levels of preeclamptic
cases did not decrease more than those of healthy pregnant
women.
17,22 In contrast, we found that the fPS activity of
preeclamptic pregnant women was lower than that of
healthy pregnant women. Similarly, in the study by Sayin
et al., there was a significant decrease in PS activity in
the preeclamptic group.
18
In a study of the homeostatic system of healthy
pregnancy, the ATIII levels were reported to decrease
slightly.
23 In our study, the ATIII levels of healthy pregnant
women were lower than those of nonpregnant women, but
it was not statistically significant. In studies performed on
preeclamptic pregnant women, ATIII levels were signifi-
cantly lower than those of healthy pregnant women.
24–26
Consistent with the literature, our study found that the
ATIII activity of preeclamptic pregnant women was lower
than that of healthy pregnant women. Pekonen et al.
reported that ATIII activity decreased only in severe
preeclamptic patients.
27 Terao et al. also reported that
ATIII activity was decreased in severe preeclamptic
patients.
28 In our study, we found decreased ATIII activity
in mild preeclamptic women compared to healthy pregnant
women. Moreover, the ATIII activity in severe preeclamptic
cases was lower than that of mild preeclamptic cases.
Weiner et al. emphasized that the decrease in plasma ATIII
activity was correlated with the stage of the disease, and it
could also be used as a test to distinguish preeclampsia and
other hypertensive diseases of pregnancy.
29 According to
our study, the lower ATIII activity level may be related to a
more severe disease stage.
Dekker et al. found that the frequency of APC-R positi-
vity in severe preeclamptic cases was 16%.
8 Lindoff et al.
found that the APC-R frequency six weeks after delivery in
women with severe preeclampsia and healthy pregnant
women was 22% and 10%, respectively, and thus, APC-R
increases the risk of preeclampsia.
30 In another study of
severe preeclamptic and healthy pregnant patients, APC-R
positivity in preeclamptic pregnant patients in the third
trimester and at three months and nine months after
delivery were 84.4%, 71.9% and 15.6%, respectively, and
these findings were higher than those of healthy pregnant
women.
31 Thus, we tested APC-R in preeclamptic pregnant
women. Similarly, in a study of severe preeclamptic and
healthy control groups, Pampus et al. found APC-R
positivity as 11.3% and 1.5%, respectively, and the factor
V Leiden mutation was present in only half of APC-R-
positive patients.
32 They did not find any difference in the
frequency of FV Leiden mutation in both groups. These
studies indicate that APC-R may be acquired. Moreover, fPS
is a cofactor of APC; therefore, temporary acquired APC-R
of preeclampsia may be related to fPS deficiency. In a study
designed similarly to our study, the APC-R frequency was
found to be 31% in preeclamptic pregnant women, 16.6% in
healthy pregnant women, and 7.6% in the control group.
33
Table 2 - Age, gestational age, ATIII, FPS, PC and APC
levels of severe and mild preeclamptic groups.
Parameters
Mild Preeclamptic
Groups
Severe Preeclamptic
Groups p Value
Age (Years) 26.40¡3.26 25.97¡3.38 p=0.614
Gestational age
(Week)
33.12¡1.50 32.80¡1.70 p=0.435
AT III (%) 91.28¡17.38 69.66¡14.74 p=0.000
fPS (%) 38.20¡10.28 39.42¡11.88 p=0.667
PC (%) 77.20¡19.87 72.84¡20.09 p=0.386
APC (sec) 130.40¡37.94 143.42¡26.18 p=0.095
Values are presented as mean ¡ SD. AT III: Antithrombin III; fPS: Free
protein S; PC: Protein C; APC: Active protein C; sec: second. p,0.05 was
considered significant.
CLINICS 2010;65(11):1119-1122 Natural coagulation inhibitors in preeclampsia
Demir C and Dilek I
1121In our study, the APC-R positivity of preeclamptic patients
was significantly higher than that of the healthy pregnant
and nonpregnant groups. We did not find a significant
difference between the healthy pregnant group and the
healthy control group. This finding is consistent with a
previous study.
34
In conclusion, preeclamptic women have more pro-
nounced deficiencies of PC, PS, ATIII and more APC
resistance compared to normal pregnant women. More
studies are needed to clarify whether these changes are
secondary to preeclampsia or are involved in pathogenesis
of the condition.
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